Bovine Lung Tissue Extract

Bovine lung tissue extract contains bioactive peptides, most notably BLP-1, which exerts antioxidant effects by scavenging free radicals through hydrogen atom transfer and single electron transfer mechanisms. Research remains in early preclinical stages, with applications spanning oxidative stress mitigation and experimental liver disease models.

Origin & History

Bovine Lung Tissue Extract is derived from cow (Bos taurus) lung tissue obtained from slaughterhouse sources. Production involves enzymatic hydrolysis using papain (3400 U/g, pH 7.70, 3.9 hours), followed by centrifugation, ultrafiltration (3-10 kDa membranes), and gel filtration chromatography to isolate bioactive peptides like BLP-1.

Historical & Cultural Context

No evidence of historical or traditional medicinal use in any healing systems was found in the research. All references focus exclusively on modern extraction methods for research purposes in antioxidant studies and tissue engineering applications.

Health Benefits

• Antioxidant activity: BLP-1 peptide showed 89.17% DPPH and 82.78% ABTS radical scavenging rates in vitro (preliminary evidence only)
• Potential liver support: Animal models of alcoholic liver disease showed therapeutic effects without cytotoxicity (no human studies)
• Tissue engineering applications: Decellularized extracts retain collagen and elastin for biomedical research (not for human consumption)
• No proven human health benefits: Zero clinical trials or human studies have been conducted
• Safety profile incomplete: Only in vitro assays showing no cytotoxicity or hemolysis at tested concentrations

How It Works

The BLP-1 peptide derived from bovine lung hydrolysate neutralizes reactive oxygen species via hydrogen atom transfer (HAT) and single electron transfer (SET) pathways, achieving 89.17% DPPH and 82.78% ABTS radical scavenging in vitro. In alcoholic liver disease animal models, lung-derived bioactive fractions appear to modulate hepatic oxidative stress markers and reduce lipid peroxidation, potentially through Nrf2 pathway activation, though this mechanism has not been confirmed in humans. Collagen and elastin-derived peptides within lung extracellular matrix fractions also interact with cellular scaffolding proteins relevant to tissue engineering applications.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses exist for bovine lung tissue extract. All available research is limited to in vitro antioxidant assays and preclinical animal models, with no PubMed-indexed human studies identified.

Clinical Summary

No human clinical trials on bovine lung tissue extract have been published as of the current evidence base. In vitro studies demonstrate strong radical scavenging activity for the BLP-1 peptide at measurable concentrations, but in vitro antioxidant assays do not reliably predict in vivo efficacy. Rodent models of alcoholic liver disease showed therapeutic effects and absence of cytotoxicity at tested doses, but animal data cannot be directly extrapolated to humans. The overall evidence quality is low, and no dosing recommendations for humans can be established from existing research.

Nutritional Profile

Bovine lung tissue extract is a protein-dominant biological material with a complex composition reflecting the structural and functional characteristics of pulmonary tissue. Protein content is the primary macronutrient, estimated at 60–80% of dry weight, predominantly comprising structural proteins: collagen (Types I, III, and IV) and elastin, which together account for approximately 30–50% of total protein in lung extracellular matrix. Functional proteins include surfactant proteins (SP-A, SP-B, SP-C, SP-D), proteoglycans (versican, decorin, biglycan), and fibronectin. Bioactive peptides such as BLP-1 (a characterized antioxidant peptide) have been isolated from enzymatic hydrolysates. Fat content is relatively low but includes phospholipids — particularly dipalmitoylphosphatidylcholine (DPPC), the primary component of pulmonary surfactant, estimated at 70–80% of surfactant lipid composition. Cholesterol and glycolipids are present in minor quantities (<5% dry weight). Carbohydrate content is low, primarily as glycosaminoglycans (heparan sulfate, chondroitin sulfate, hyaluronic acid) bound to proteoglycans. Micronutrient content includes iron (present in hemoglobin and myoglobin residues, approximately 2–5 mg/100g dry weight), zinc (associated with metalloproteinases, ~3–6 mg/100g), copper (lysyl oxidase cofactor, ~0.5–1 mg/100g), selenium (as selenocysteine in glutathione peroxidase residues), and B vitamins including B12 (~1–2 µg/100g) and riboflavin (B2, ~0.2–0.4 mg/100g). Bioavailability is highly dependent on processing method: raw extracts have limited protein bioavailability due to complex cross-linking of collagen and elastin; enzymatic hydrolysis significantly improves amino acid and peptide absorption, yielding bioactive fragments including hydroxyproline-rich peptides (~10–14% of collagen-derived amino acids). Growth factors including TGF-β and FGF may be retained in minimally processed extracts but are largely denatured under heat or chemical processing conditions.

Preparation & Dosage

No clinically studied dosage ranges exist due to absence of human trials. Preclinical studies only describe extraction yields of peptide fractions (<3 kDa) without standardization or dosing guidelines for human consumption. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other organ-derived supplements, antioxidants like NAC, liver support compounds, collagen peptides, elastin supplements

Safety & Interactions

No formal human safety studies, dose-ranging trials, or pharmacovigilance data exist for bovine lung tissue extract as a supplement. Individuals with bovine protein allergies or sensitivities to animal-derived organ products should avoid this ingredient due to potential allergic reactions. Theoretical concerns exist regarding interactions with anticoagulant medications if the extract contains heparin-like glycosaminoglycans naturally present in lung tissue. Pregnant or breastfeeding individuals should avoid use entirely given the complete absence of safety data in these populations.